Thomas Miller/Linkedin
Jun 16, 2025, 15:00
Thomas Miller: Unlocking Smarter BCL-2 Inhibitor Therapies After EHA 2025
Thomas Miller, Principal Investigator at Institut Paoli-Calmettes, shared a post on LinkedIn:
“Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Excellent final day at EHA2025. Institut Paoli-Calmettes was particularly engaged by the dedicated session on BCL-2 inhibitor therapies, highlighted by Sylvain Garciaz’s insightful presentation on inherent and acquired resistance mechanisms.
This critical discussion sparks a vital question: How can we develop smarter strategies to utilize BCL-2 inhibitors, circumvent multi-drug resistance, and unlock new combination opportunities, especially for the elderly patient population?
At Institut Paoli-Calmettes, we are committed to exploring these avenues, pushing the boundaries of research to enhance treatment efficacy and improve patient outcomes.
Let’s continue this crucial conversation and collaborate on innovative solutions!”
Find more posts featuring EHA 2025.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia